Unmet needs in treating itch: reaching beyond eczema

References

• Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. J Invest Dermatol. 2014;134(6):1–23. doi:10.1038/jid.2013.446.
   Web of Science ®Google Scholar
• Pereira MP, Ständer S. Assessment of severity and burden of pruritus. Allergology International. 2017;66(1):3–7. doi:10.1016/j.alit.2016.08.009.
   PubMed Web of Science ®Google Scholar
• Lobefaro F, Gualdi G, Di Nuzzo S, et al. Atopic dermatitis: clinical aspects and unmet needs. Biomedicines. 2022;10(11):2927. doi:10.3390/biomedicines10112927.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Mohawk JA, Cirulli J, et al. Burden of disease and unmet needs in atopic dermatitis: results from a patient survey. Dermatitis. 2023;34(2):135–144. doi:10.1089/derm.2022.29015.jsi.
   PubMed Web of Science ®Google Scholar
• Buhl T, Werfel T. Atopic dermatitis - perspectives and unmet medical needs. J Dtsch Dermatol Ges. 2023;21(4):349–353.
   Web of Science ®Google Scholar
• Kolkhir P, Akdis CA, Akdis M, et al. Type 2 chronic inflammatory diseases: targets, therapies and unmet needs. Nat Rev Drug Discov. 2023;22(9):743–767. doi:10.1038/s41573-023-00750-1.
   PubMed Web of Science ®Google Scholar
• Ujiie H, Rosmarin D, Schön MP, et al. Unmet medical needs in chronic, non-communicable inflammatory skin diseases. Front Med (Lausanne). 2022;9:875492. doi:10.3389/fmed.2022.875492.
   PubMed Web of Science ®Google Scholar
• Ständer S, Stumpf A, Osada N, et al. Gender differences in chronic pruritus: women present different morbidity, more scratch lesions and higher burden. Br J Dermatol. 2013;168(6):1273–1280. doi:10.1111/bjd.12267.
   PubMed Web of Science ®Google Scholar
• Kursewicz C, Fowler E, Rosen J, et al. Sex differences in the perception of itch and quality of life in patients with chronic pruritus in the United States. Itch. 2020;5(3):e41–e41. doi:10.1097/itx.0000000000000041.
   Google Scholar
• Peters MG, Di Bisceglie AM, Kowdley KV, et al. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology. 2007;46(3):769–775. doi:10.1002/hep.21759.
   PubMed Web of Science ®Google Scholar
• Nzerue CM, Demissochew H, Tucker JK. Race and kidney disease: role of social and environmental factors. J Natl Med Assoc. 2002;94(8 Suppl):28s–38s.
   PubMed Web of Science ®Google Scholar
• Galderma announces regulatory filing acceptance for its investigational treatment in prurigo nodularis and atopic dermatitis in the U.S. and EU; February 14, 2024 [press release].
   Google Scholar
• Han Y, Woo YR, Cho SH, et al. Itch and Janus Kinase Inhibitors. Acta Derm Venereol. 2023;103:adv00869. doi:10.2340/actadv.v103.5346.
   PubMed Web of Science ®Google Scholar
• Fourzali K, Yosipovitch G. Safety considerations when using drugs to treat pruritus. Expert Opin Drug Saf. 2020;19(4):467–477. doi:10.1080/14740338.2020.1728252.
   PubMed Web of Science ®Google Scholar
• Farrah G, Spruijt O, McCormack C, et al. A systematic review on the management of pruritus in patients with cutaneous T-cell lymphoma. Itch. 2021;6(2):e55–e55. doi:10.1097/itx.0000000000000055.
   Google Scholar
• Kim BS, Berger TG, Yosipovitch G. Chronic pruritus of unknown origin (CPUO): uniform nomenclature and diagnosis as a pathway to standardized understanding and treatment. J Am Acad Dermatol. 2019;81(5):1223–1224. doi:10.1016/j.jaad.2019.07.080.
   PubMed Web of Science ®Google Scholar
• Roh YS, Choi J, Sutaria N, et al. Itch: epidemiology, clinical presentation, and diagnostic workup. J Am Acad Dermatol. 2022;86(1):1–14. doi:10.1016/j.jaad.2021.07.076.
   PubMed Web of Science ®Google Scholar
• Okano M, Hirahara K, Kiuchi M, et al. Interleukin-33-activated neuropeptide CGRP-producing memory Th2 cells cooperate with somatosensory neurons to induce conjunctival itch. Immunity. 2022;55(12):2352–2368.e2357. doi:10.1016/j.immuni.2022.09.016.
   PubMed Web of Science ®Google Scholar
• Wang F, Kim BS. Itch: a paradigm of neuroimmune crosstalk. Immunity. 2020;52(5):753–766. doi:10.1016/j.immuni.2020.04.008.
   PubMed Web of Science ®Google Scholar
• Wang F, Trier AM, Li F, et al. A basophil-neuronal axis promotes itch. Cell. 2021;184(2):422–440.e417. doi:10.1016/j.cell.2020.12.033.
   PubMed Web of Science ®Google Scholar
• Nattkemper LA, Kim BS, Yap QV, et al. Increased systemic levels of centrally acting B-type Natriuretic Peptide are associated with chronic Itch of different types. J Invest Dermatol. 2024. doi:10.1016/j.jid.2024.02.026.
   PubMedGoogle Scholar
• Ju T, Labib A, Vander Does A, et al. Therapeutics in chronic pruritus of unknown origin. Itch. 2023;8(1):e64–e64. doi:10.1097/itx.0000000000000064.
   Google Scholar
• Kwatra S, Bordeaux Z, Pritchard T, et al. Efficacy, safety, and mechanism of action of abrocitinib in the treatment of prurigo nodularis and chronic pruritus of unknown origin. Presented at: European Academy of Dermatology and Venereology Congress 2023; 2023 October 11-14, Berlin, Germany.
   Google Scholar
• Valdes-Rodriguez R, Mollanazar NK, González-Muro J, et al. Itch prevalence and characteristics in a Hispanic geriatric population: a comprehensive study using a standardized itch questionnaire. Acta Derm Venereol. 2015;95(4):417–421.
   PubMed Web of Science ®Google Scholar
• Gunalan P, Indradevi R, Oudeacoumar P, et al. Pattern of skin diseases in geriatric patients attending tertiary care centre. jemds. 2017;6(20):1566–1570. +. doi:10.14260/Jemds/2017/344.
   Google Scholar
• Yalçin B, Tamer E, Toy GG, et al. The prevalence of skin diseases in the elderly: analysis of 4099 geriatric patients. Int J Dermatol. 2006;45(6):672–676. doi:10.1111/j.1365-4632.2005.02607.x.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Hinami K, Trick WE, et al. Itch in the general internal medicine setting: a cross-sectional study of prevalence and quality-of-life effects. Am J Clin Dermatol. 2016;17(6):681–690. doi:10.1007/s40257-016-0215-3.
   PubMed Web of Science ®Google Scholar
• Chung BY, Um JY, Kim JC, et al. Pathophysiology and treatment of pruritus in elderly. Int J Mol Sci. 2021;22(1):174. doi:10.3390/ijms22010174.
   Web of Science ®Google Scholar
• Garibyan L, Chiou AS, Elmariah SB. Advanced aging skin and itch: addressing an unmet need. Dermatol Ther. 2013;26(2):92–103. doi:10.1111/dth.12029.
   PubMed Web of Science ®Google Scholar
• Bellinato F, Maurelli M, Gisondi P, et al. Clinical features and treatments of transient acantholytic dermatosis (Grover’s disease): a systematic review. J Deutsche Derma Gesell. 2020;18(8):826–833. doi:10.1111/ddg.14202.
   Google Scholar
• Aldana PC, Khachemoune A. Grover disease: review of subtypes with a focus on management options. Int J Dermatol. 2020;59(5):543–550. doi:10.1111/ijd.14700.
   PubMed Web of Science ®Google Scholar
• Gantz M, Butler D, Goldberg M, et al. Atypical features and systemic associations in extensive cases of Grover disease: a systematic review. J Am Acad Dermatol. 2017;77(5):952–957.e951. doi:10.1016/j.jaad.2017.06.041.
   PubMed Web of Science ®Google Scholar
• Fourzali KM, Yosipovitch G. Management of itch in the elderly: a review. Dermatol Ther (Heidelb). 2019;9(4):639–653. doi:10.1007/s13555-019-00326-1.
   PubMed Web of Science ®Google Scholar
• Shevchenko A, Valdes-Rodriguez R, Yosipovitch G. Causes, pathophysiology, and treatment of pruritus in the mature patient. Clin Dermatol. 2018;36(2):140–151. doi:10.1016/j.clindermatol.2017.10.005.
   PubMed Web of Science ®Google Scholar
• Pisoni RL, Wikström B, Elder SJ, et al. Pruritus in haemodialysis patients: international results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Nephrol Dial Transplant. 2006;21(12):3495–3505. doi:10.1093/ndt/gfl461.
   PubMed Web of Science ®Google Scholar
• Schut C, Mollanazar NK, Kupfer J, et al. Psychological interventions in the treatment of chronic itch. Acta Derm Venereol. 2016;96(2):157–161. doi:10.2340/00015555-2177.
   PubMed Web of Science ®Google Scholar
• Bin Saif GA, Ericson ME, Yosipovitch G. The itchy scalp–scratching for an explanation. Exp Dermatol. 2011;20(12):959–968. doi:10.1111/j.1600-0625.2011.01389.x.
   PubMed Web of Science ®Google Scholar
• Rattanakaemakorn P, Suchonwanit P. Scalp pruritus: review of the pathogenesis, diagnosis, and management. Biomed Res Int. 2019;2019:1268430–1268411. doi:10.1155/2019/1268430.
   PubMed Web of Science ®Google Scholar
• Misery L, Ständer S, Szepietowski JC, et al. Definition of sensitive skin: an expert position paper from the special interest group on sensitive skin of the international forum for the study of itch. Acta Derm Venereol. 2017;97(1):4–6.
   PubMed Web of Science ®Google Scholar
• Misery L, Rahhali N, Ambonati M, et al. Evaluation of sensitive scalp severity and symptomatology by using a new score. J Eur Acad Dermatol Venereol. 2011;25(11):1295–1298. doi:10.1111/j.1468-3083.2010.03968.x.
   PubMed Web of Science ®Google Scholar
• Choragudi S, Andrade L, Yosipovitch G. Genital pruritus is associated with longer hospital stays, higher costs and increased odds of psychiatric hospitalization among inpatient adults with pruritus in the United States—National inpatient sample (2012–2015). JEADV Clinical Practice. 2023;3(1):233–238. doi:10.1002/jvc2.281.
   Google Scholar
• Hadasik K, Arasiewicz H, Brzezińska-Wcisło L. Assessment of the anxiety and depression among patients with idiopathic pruritus ani. Postepy Dermatol Alergol. 2021;38(4):689–693. doi:10.5114/ada.2021.108906.
   PubMed Web of Science ®Google Scholar
• Schubert MC, Sridhar S, Schade RR, et al. What every gastroenterologist needs to know about common anorectal disorders. World J Gastroenterol. 2009;15(26):3201–3209. doi:10.3748/wjg.15.3201.
   PubMed Web of Science ®Google Scholar
• Swamiappan M. Anogenital pruritus - an overview. J Clin Diagn Res. 2016;10(4):We01-03–WE03. doi:10.7860/JCDR/2016/18440.7703.
   Google Scholar
• Parés D, Abcarian H. Management of common benign anorectal disease: what all physicians need to know. Am J Med. 2018;131(7):745–751. doi:10.1016/j.amjmed.2018.01.050.
   PubMed Web of Science ®Google Scholar
• Daniel GL, Longo WE, Vernava AM.3rd. Pruritus ani. Causes and concerns. Dis Colon Rectum. 1994;37(7):670–674. doi:10.1007/BF02054410.
   PubMed Web of Science ®Google Scholar
• Jakubauskas M, Dulskas A. Evaluation, management and future perspectives of anal pruritus: a narrative review. Eur J Med Res. 2023;28(1):57. doi:10.1186/s40001-023-01018-5.
   PubMed Web of Science ®Google Scholar
• Rosen JD, Fostini AC, Yosipovitch G. Diagnosis and management of neuropathic itch. Dermatol Clin. 2018;36(3):213–224. doi:10.1016/j.det.2018.02.005.
   PubMed Web of Science ®Google Scholar
• Cohen AD, Vander T, Medvendovsky E, et al. Neuropathic scrotal pruritus: anogenital pruritus is a symptom of lumbosacral radiculopathy. J Am Acad Dermatol. 2005;52(1):61–66. doi:10.1016/j.jaad.2004.04.039.
   PubMed Web of Science ®Google Scholar
• Felemovicius I, Ganz RA, Saremi M, et al. SOOTHER TRIAL: observational study of an over-the-counter ointment to heal anal itch. Front Med (Lausanne). 2022;9:890883. doi:10.3389/fmed.2022.890883.
   PubMed Web of Science ®Google Scholar
• Weichert GE. An approach to the treatment of anogenital pruritus. Dermatol Ther. 2004;17(1):129–133. doi:10.1111/j.1396-0296.2004.04013.x.
   PubMedGoogle Scholar
• Albuquerque A. Anal pruritus: don’t look away. World J Gastrointest Endosc. 2024;16(3):112–116. doi:10.4253/wjge.v16.i3.112.
   PubMed Web of Science ®Google Scholar
• Jia W, Li Q, Ni J, et al. Efficacy and safety of methylene blue injection for intractable idiopathic pruritus ani: a single-arm metaanalysis and systematic review. Tech Coloproctol. 2023;27(10):813–825. doi:10.1007/s10151-023-02825-y.
   PubMed Web of Science ®Google Scholar
• Yang EJ, Murase JE. Recalcitrant anal and genital pruritus treated with dupilumab. Int J Womens Dermatol. 2018;4(4):223–226. doi:10.1016/j.ijwd.2018.08.010.
   PubMedGoogle Scholar
• Ryan C, Sadlier M, De Vol E, et al. Genital psoriasis is associated with significant impairment in quality of life and sexual functioning. J Am Acad Dermatol. 2015;72(6):978–983. doi:10.1016/j.jaad.2015.02.1127.
   PubMed Web of Science ®Google Scholar
• Woelber L, Prieske K, Mendling W, et al. Vulvar pruritus-causes, diagnosis and therapeutic approach. Dtsch Arztebl Int. 2020;116(8):126–133. doi:10.3238/arztebl.2020.0126.
   PubMedGoogle Scholar
• Harlow BL, Wise LA, Stewart EG. Prevalence and predictors of chronic lower genital tract discomfort. Am J Obstet Gynecol. 2001;185(3):545–550. doi:10.1067/mob.2001.116748.
   PubMed Web of Science ®Google Scholar
• Savas JA, Pichardo RO. Female genital itch. Dermatol Clin. 2018;36(3):225–243. doi:10.1016/j.det.2018.02.006.
   PubMed Web of Science ®Google Scholar
• Alani A, McDonald L, Abdelrahman W, et al. Vulvar itch. BMJ. 2019;364:l83. doi:10.1136/bmj.l83.
   PubMedGoogle Scholar
• Corazza M, Borghi A, Minghetti S, et al. Effectiveness of silk fabric underwear as an adjuvant tool in the management of vulvar lichen simplex chronicus: results of a double-blind randomized controlled trial. Menopause. 2015;22(8):850–856. doi:10.1097/GME.0000000000000410.
   PubMed Web of Science ®Google Scholar
• van der Meijden WI, Boffa MJ, Ter Harmsel WA, et al. 2016 European guideline for the management of vulval conditions. J Eur Acad Dermatol Venereol. 2017;31(6):925–941. doi:10.1111/jdv.14096.
   PubMed Web of Science ®Google Scholar
• Robinson C, Downs E, De la Caridad Gomez Y, et al. Notalgia paresthetica review: update on presentation, pathophysiology, and treatment. Clin Pract. 2023;13(1):315–325. doi:10.3390/clinpract13010029.
   PubMed Web of Science ®Google Scholar
• Kavanagh KJ, Mattei PL, Lawrence R, et al. Brachioradial pruritus: an etiologic review and treatment summary. Cutis. 2023;112(2):84–87. doi:10.12788/cutis.0828.
   PubMed Web of Science ®Google Scholar
• Howard M, Sahhar L, Andrews F, et al. Notalgia paresthetica: a review for dermatologists. Int J Dermatol. 2018;57(4):388–392. doi:10.1111/ijd.13853.
   PubMed Web of Science ®Google Scholar
• Mülkoğlu C, Nacır B. Notalgia paresthetica: clinical features, radiological evaluation, and a novel therapeutic option. BMC Neurol. 2020;20(1):191. doi:10.1186/s12883-020-01773-6.
   PubMed Web of Science ®Google Scholar
• Ellis C. Notalgia paresthetica: the unreachable itch. Dermatol Pract Concept. 2013;3(1):3–6. doi:10.5826/dpc.0301a02.
   PubMedGoogle Scholar
• Kim BS, Bissonnette R, Nograles K, et al. Phase 2 trial of difelikefalin in notalgia paresthetica. N Engl J Med. 2023;388(6):511–517. doi:10.1056/NEJMoa2210699.
   PubMed Web of Science ®Google Scholar
• Bacci ED, Currie BM, Wilson R, et al. Understanding the patient experience of living with notalgia paresthetica: a qualitative interview study. JAAD Int. 2022;8:94–101. doi:10.1016/j.jdin.2022.04.003.
   PubMedGoogle Scholar
• Lipman ZM, Ven Yap Q, Nattkemper L, et al. Association of neuropathic itch with patients’ quality of life. JAMA Dermatol. 2021;157(8):997–998. doi:10.1001/jamadermatol.2021.2010.
   PubMed Web of Science ®Google Scholar
• Burshtein A, Burshtein J, Rekhtman S. Extragenital lichen sclerosus: a comprehensive review of clinical features and treatment. Arch Dermatol Res. 2023;315(3):339–346. doi:10.1007/s00403-022-02397-1.
   PubMed Web of Science ®Google Scholar
• Marfatia Y, Surani A, Baxi R. Genital lichen sclerosus et atrophicus in females: an update. Indian J Sex Transm Dis AIDS. 2019;40(1):6–12. doi:10.4103/ijstd.IJSTD_23_19.
   PubMed Web of Science ®Google Scholar
• De Luca DA, Papara C, Vorobyev A, et al. Lichen sclerosus: the 2023 update. Front Med (Lausanne). 2023;10:1106318. doi:10.3389/fmed.2023.1106318.
   PubMed Web of Science ®Google Scholar
• Vulvar lichen sclerosus with evolution to squamous cell carcinoma. J Am Acad Dermatol. 2012;66(4):AB160. doi:10.1016/j.jaad.2011.11.672.
   Web of Science ®Google Scholar
• Lee A, Fischer G. Diagnosis and treatment of vulvar lichen sclerosus: an update for dermatologists. Am J Clin Dermatol. 2018;19(5):695–706. doi:10.1007/s40257-018-0364-7.
   PubMed Web of Science ®Google Scholar
• Wehbe-Alamah H, Kornblau BL, Haderer J, et al. Silent no more! The lived experiences of women with lichen sclerosis. J Am Acad Nurse Pract. 2012;24(8):499–505. doi:10.1111/j.1745-7599.2012.00715.x.
   PubMed Web of Science ®Google Scholar
• Yalici-Armagan B, Bostan E, Akdogan N, et al. Paediatric lichen sclerosus et atrophicus: a retrospective analysis of 38 paediatric patients. Int J Clin Pract. 2021;75(10):e14661. doi:10.1111/ijcp.14661.
   PubMedGoogle Scholar
• Lewis FM, Tatnall FM, Velangi SS, et al. British Association of Dermatologists guidelines for the management of lichen sclerosus, 2018. Br J Dermatol. 2018;178(4):839–853. doi:10.1111/bjd.16241.
   PubMed Web of Science ®Google Scholar
• Charifa ABT, Harris BW. Lichen simplex chronicus. In StatPearls. Treasure Island (FL)StatPearls Publishing; 2024; [Updated 2023 Aug 7]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499991/
   Google Scholar
• Ju T, Vander Does A, Mohsin N, et al. Lichen simplex chronicus itch: an update. Acta Derm Venereol. 2022;102:adv00796. doi:10.2340/actadv.v102.4367.
   PubMed Web of Science ®Google Scholar
• Juarez MC, Kwatra SG. A systematic review of evidence based treatments for lichen simplex chronicus. J Dermatolog Treat. 2021;32(7):684–692. doi:10.1080/09546634.2019.1708856.
   PubMed Web of Science ®Google Scholar
• Barak SL, Michel D, Brener E, et al. 629 Evaluating the safety and efficacy of topical KM-001, a TRPV3 inhibitor, for treatment of pruritus in patients with Lichen Simplex Chronicus (LSC): a first in human, double-blind, randomized vehicle-controlled study. J Invest Dermatol. 2023;143(5):S108. doi:10.1016/j.jid.2023.03.636.
   Web of Science ®Google Scholar
• Weyers W, Weyers I, Bonczkowitz M, et al. Lichen amyloidosus: a consequence of scratching. J Am Acad Dermatol. 1997;37(6):923–928. doi:10.1016/s0190-9622(97)70066-5.
   PubMed Web of Science ®Google Scholar
• Soriano LF, McGrath C, Hawthorne M, et al. An intensely pruritic pebbled presentation. Dermatol Online J. 2018;24(2):13030/qt6tp6f9c4.
   PubMedGoogle Scholar
• Pálla S, Kuroli E, Tóth EA, et al. Primary localized cutaneous amyloidosis in central Europe: a retrospective monocentric study on epidemiology and therapy. J Clin Med. 2023;12(24):7672. doi:10.3390/jcm12247672.
   PubMed Web of Science ®Google Scholar
• Salim T, Shenoi SD, Balachandran C, et al. Lichen amyloidosus: a study of clinical, histopathologic and immunofluorescence findings in 30 cases. Indian J Dermatol Venereol Leprol. 2005;71(3):166–169. doi:10.4103/0378-6323.16230.
   PubMedGoogle Scholar
• Tey HL, Cao T, Nattkemper LA, et al. Pathophysiology of pruritus in primary localized cutaneous amyloidosis. Br J Dermatol. 2016;174(6):1345–1350. doi:10.1111/bjd.14391.
   PubMed Web of Science ®Google Scholar
• Maddison B, Namazi MR, Samuel LS, et al. Unexpected diminished innervation of epidermis and dermoepidermal junction in lichen amyloidosus. Br J Dermatol. 2008;159(2):403–406. doi:10.1111/j.1365-2133.2008.08685.x.
   PubMed Web of Science ®Google Scholar
• Chia B, Tan A, Tey HL. Primary localized cutaneous amyloidosis: association with atopic dermatitis. J Eur Acad Dermatol Venereol. 2014;28(6):810–813. doi:10.1111/jdv.12144.
   PubMed Web of Science ®Google Scholar
• Hashimoto T, Kursewicz CD, Fayne RA, et al. Pathophysiologic mechanisms of itch in bullous pemphigoid. J Am Acad Dermatol. 2020;83(1):53–62. doi:10.1016/j.jaad.2019.07.060.
   PubMed Web of Science ®Google Scholar
• Kridin K, Ludwig RJ. The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne). 2018;5:220. doi:10.3389/fmed.2018.00220.
   PubMed Web of Science ®Google Scholar
• Briand C, Gourier G, Poizeau F, et al. Characteristics of pruritus in bullous pemphigoid and impact on quality of life: a prospective cohort study. Acta Derm Venereol. 2020;100(18):adv00320. doi:10.2340/00015555-3683.
   PubMed Web of Science ®Google Scholar
• Ständer S, Hammers CM, Vorobyev A, et al. The impact of lesional inflammatory cellular infiltrate on the phenotype of bullous pemphigoid. J Eur Acad Dermatol Venereol. 2021;35(8):1702–1711. doi:10.1111/jdv.17303.
   PubMed Web of Science ®Google Scholar
• Limberg MM, Weihrauch T, Gray N, et al. Eosinophils, basophils, and neutrophils in bullous pemphigoid. Biomolecules. 2023;13(7):1019. doi:10.3390/biom13071019.
   PubMed Web of Science ®Google Scholar
• Messingham KN, Crowe TP, Fairley JA. The intersection of IgE autoantibodies and eosinophilia in the pathogenesis of bullous pemphigoid. Front Immunol. 2019;10:2331. doi:10.3389/fimmu.2019.02331.
   PubMed Web of Science ®Google Scholar
• Lamberts A, Kotnik N, Diercks GFH, et al. IgE autoantibodies in serum and skin of non-bullous and bullous pemphigoid patients. J Eur Acad Dermatol Venereol. 2021;35(4):973–980. doi:10.1111/jdv.16996.
   PubMed Web of Science ®Google Scholar
• Chebani R, Lombart F, Chaby G, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. British Journal of Dermatology. 2023;190(2):258–265. doi:10.1093/bjd/ljad369.
   Web of Science ®Google Scholar
• Meijer J, Lamberts A, Luijendijk D, et al. Prevalence of pruritus and pemphigoid in nursing home residents (SSENIOR): a cross-sectional study of an unmet need. J Invest Dermatol. 2018;138(5):S48. doi:10.1016/j.jid.2018.03.286.
   Web of Science ®Google Scholar
• Meijer JM, Lamberts A, Luijendijk HJ, et al. Prevalence of pemphigoid as a potentially unrecognized cause of pruritus in nursing home residents. JAMA Dermatol. 2019;155(12):1423–1424. doi:10.1001/jamadermatol.2019.3308.
   PubMed Web of Science ®Google Scholar
• Lamberts A, Meijer JM, Jonkman MF. Nonbullous pemphigoid: a systematic review. J Am Acad Dermatol. 2018;78(5):989–995.e982. doi:10.1016/j.jaad.2017.10.035.
   PubMed Web of Science ®Google Scholar
• Meijer JM, Diercks GFH, de Lang EWG, et al. Assessment of diagnostic strategy for early recognition of bullous and nonbullous variants of pemphigoid. JAMA Dermatol. 2019;155(2):158–165. doi:10.1001/jamadermatol.2018.4390.
   PubMed Web of Science ®Google Scholar
• Ujiie H, Iwata H, Yamagami J, et al. Japanese guidelines for the management of pemphigoid (including epidermolysis bullosa acquisita). J Dermatol. 2019;46(12):1102–1135. doi:10.1111/1346-8138.15111.
   PubMed Web of Science ®Google Scholar
• Borradori L, Van Beek N, Feliciani C, et al. Updated S2 K guidelines for the management of bullous pemphigoid initiated by the European Academy of Dermatology and Venereology (EADV). Acad Dermatol Venereol. 2022;36(10):1689–1704. doi:10.1111/jdv.18220.
   PubMed Web of Science ®Google Scholar
• Chalmers JR, Wojnarowska F, Kirtschig G, et al. A randomised controlled trial to compare the safety, effectiveness and cost-effectiveness of doxycycline (200 mg/day) with that of oral prednisolone (0.5 mg/kg/day) for initial treatment of bullous pemphigoid: the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) trial. Health Technol Assess. 2017;21(10):1–90. doi:10.3310/hta21100.
   Web of Science ®Google Scholar
• Ujiie I, Iwata H, Yoshimoto N, et al. Clinical characteristics and outcomes of bullous pemphigoid patients with versus without oral prednisolone treatment. J Dermatol. 2021;48(4):502–510. doi:10.1111/1346-8138.15816.
   PubMed Web of Science ®Google Scholar
• Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150(1):25–33. doi:10.1001/jamadermatol.2013.5757.
   PubMed Web of Science ®Google Scholar
• Oren-Shabtai M, Mimouni D, Nosrati A, et al. Biological treatment for bullous pemphigoid. Front Immunol. 2023;14:1157250. doi:10.3389/fimmu.2023.1157250.
   PubMed Web of Science ®Google Scholar
• Abduelmula A, Mufti A, Chong DHY, et al. Biologic treatment outcomes in refractory bullous pemphigoid: an evidence-based review. JAAD Int. 2022;9:142–145. doi:10.1016/j.jdin.2022.09.001.
   PubMedGoogle Scholar
• Bolotin D, Petronic-Rosic V. Dermatitis herpetiformis: part I. Epidemiology, pathogenesis, and clinical presentation. J Am Acad Dermatol. 2011;64(6):1017–1024. doi:10.1016/j.jaad.2010.09.777.
   PubMed Web of Science ®Google Scholar
• Salmi TT, Hervonen K, Kautiainen H, et al. Prevalence and incidence of dermatitis herpetiformis: a 40-year prospective study from Finland. Br J Dermatol. 2011;165(2):354–359. doi:10.1111/j.1365-2133.2011.10385.x.
   PubMed Web of Science ®Google Scholar
• Singh P, Arora A, Strand TA, et al. Global prevalence of celiac disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2018;16(6):823–836.e822. doi:10.1016/j.cgh.2017.06.037.
   PubMed Web of Science ®Google Scholar
• Graziano M, Rossi M. An update on the cutaneous manifestations of coeliac disease and non-coeliac gluten sensitivity. Int Rev Immunol. 2018;37(6):291–300. doi:10.1080/08830185.2018.1533008.
   PubMed Web of Science ®Google Scholar
• Nguyen CN, Kim SJ. Dermatitis herpetiformis: an update on diagnosis, disease monitoring, and management. Medicina (Kaunas). 2021;57(8):843. doi:10.3390/medicina57080843.
   Web of Science ®Google Scholar
• Antiga E, Maglie R, Quintarelli L, et al. Dermatitis herpetiformis: novel perspectives. Front Immunol. 2019;10:1290. doi:10.3389/fimmu.2019.01290.
   PubMed Web of Science ®Google Scholar
• Bonciani D, Quintarelli L, Del Bianco E, et al. Serum levels and tissue expression of interleukin-31 in dermatitis herpetiformis and bullous pemphigoid. J Dermatol Sci. 2017;87(2):210–212. doi:10.1016/j.jdermsci.2017.04.008.
   PubMed Web of Science ®Google Scholar
• Yahya A, Gideon PS. Characterizing pruritus in autoimmune connective tissue diseases. J Drugs Dermatol. 2019;18(10):995–998.
   PubMed Web of Science ®Google Scholar
• Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin-31. Br J Dermatol. 2018;179(3):669–678. doi:10.1111/bjd.16498.
   PubMed Web of Science ®Google Scholar
• Wong LS, Yen YT. Autoimmune connective tissue diseases-related pruritus: proper diagnosis and possible mechanisms. Diagnostics (Basel). 2022;12(7):1772. doi:10.3390/diagnostics12071772.
   Google Scholar
• Razykov I, Levis B, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis: an updated analysis of 959 patients. Rheumatology (Oxford). 2013;52(11):2056–2061. doi:10.1093/rheumatology/ket275.
   PubMed Web of Science ®Google Scholar
• Stull CM, Weaver LA, Valdes-Rodriguez R, et al. Characteristics of chronic itch in systemic sclerosis: a cross-sectional survey. Acta Derm Venereol. 2018;98(8):793–794. doi:10.2340/00015555-2966.
   PubMed Web of Science ®Google Scholar
• Théréné C, Brenaut E, Sonbol H, et al. Itch and systemic sclerosis: frequency, clinical characteristics and consequences. Br J Dermatol. 2017;176(5):1392–1393. doi:10.1111/bjd.14998.
   PubMed Web of Science ®Google Scholar
• Razykov I, Thombs BD, Hudson M, et al. Prevalence and clinical correlates of pruritus in patients with systemic sclerosis. Arthritis Rheum. 2009;61(12):1765–1770. doi:10.1002/art.25010.
   PubMedGoogle Scholar
• Racine M, Hudson M, Baron M, et al. The impact of pain and itch on functioning and health-related quality of life in systemic sclerosis: an exploratory study. J Pain Symptom Manage. 2016;52(1):43–53. doi:10.1016/j.jpainsymman.2015.12.314.
   PubMed Web of Science ®Google Scholar
• Akhmetshina A, Dees C, Busch N, et al. The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis. Arthritis Rheum. 2009;60(4):1129–1136. doi:10.1002/art.24395.
   PubMed Web of Science ®Google Scholar
• Kim HJ. Pruritus in autoimmune connective tissue diseases. Ann Transl Med. 2021;9(5):441–441. doi:10.21037/atm-20-4894.
   PubMed Web of Science ®Google Scholar
• Meridor K, Berookhim J, Levy Y. Low dose naloxone for pruritus in systemic sclerosis: case series and literature review. Medicine (Baltimore). 2022;101(4):e28653. doi:10.1097/MD.0000000000028653.
   PubMed Web of Science ®Google Scholar
• Frech T, Novak K, Revelo MP, et al. Low-dose naltrexone for pruritus in systemic sclerosis. Int J Rheumatol. 2011;2011:804296–804295. doi:10.1155/2011/804296.
   PubMedGoogle Scholar
• Stull C, Lavery MJ, Yosipovitch G. Advances in therapeutic strategies for the treatment of pruritus. Expert Opin Pharmacother. 2016;17(5):671–687. doi:10.1517/14656566.2016.1127355.
   PubMed Web of Science ®Google Scholar
• Herrick AL, Assassi S, Denton CP. Skin involvement in early diffuse cutaneous systemic sclerosis: an unmet clinical need. Nat Rev Rheumatol. 2022;18(5):276–285. doi:10.1038/s41584-022-00765-9.
   PubMed Web of Science ®Google Scholar
• Pope JE, Denton CP, Johnson SR, et al. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19(4):212–226. doi:10.1038/s41584-023-00909-5.
   PubMed Web of Science ®Google Scholar
• Khanna D, Lescoat A, Roofeh D, et al. Systemic sclerosis-associated interstitial lung disease: how to incorporate two food and drug administration-approved therapies in clinical practice. Arthritis Rheumatol. 2022;74(1):13–27. doi:10.1002/art.41933.
   PubMed Web of Science ®Google Scholar
• Kowal-Bielecka O, Fransen J, Avouac J, et al. Update of EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2017;76(8):1327–1339. doi:10.1136/annrheumdis-2016-209909.
   PubMed Web of Science ®Google Scholar
• Denton CP, Hughes M, Gak N, et al. BSR and BHPR guideline for the treatment of systemic sclerosis. Rheumatology. 2016;55(10):1906–1910. doi:10.1093/rheumatology/kew224.
   PubMed Web of Science ®Google Scholar
• Hundley JL, Carroll CL, Lang W, et al. Cutaneous symptoms of dermatomyositis significantly impact patients’ quality of life. J Am Acad Dermatol. 2006;54(2):217–220. doi:10.1016/j.jaad.2004.12.015.
   PubMed Web of Science ®Google Scholar
• Robinson ES, Feng R, Okawa J, et al. Improvement in the cutaneous disease activity of patients with dermatomyositis is associated with a better quality of life. Br J Dermatol. 2015;172(1):169–174. doi:10.1111/bjd.13167.
   PubMed Web of Science ®Google Scholar
• Vleugels RA, Callen J, Ofori AO. Cutaneous dermatomyositis in adults: overview and initial management; 2022, October 12. UpToDate. https://www.uptodate.com/contents/cutaneous-dermatomyositis-in-adults-overview-and-initial-management.
   Google Scholar
• Anyanwu CO, Chansky PB, Feng R, et al. The systemic management of cutaneous dermatomyositis: results of a stepwise strategy. Int J Womens Dermatol. 2017;3(4):189–194. doi:10.1016/j.ijwd.2017.05.001.
   PubMedGoogle Scholar
• Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial. J Invest Dermatol. 2022;142(10):2651–2659.e2651. doi:10.1016/j.jid.2022.03.029.
   PubMed Web of Science ®Google Scholar
• Spiera R, Hummers L, Chung L, et al. Safety and efficacy of lenabasum in a phase II, randomized, placebo-controlled trial in adults with systemic sclerosis. Arthritis Rheumatol. 2020;72(8):1350–1360.
   PubMed Web of Science ®Google Scholar
• Gerami P, Rosen S, Kuzel T, et al. Folliculotropic mycosis fungoides: an aggressive variant of cutaneous T-cell lymphoma. Arch Dermatol. 2008;144(6):738–746. doi:10.1001/archderm.144.6.738.
   PubMedGoogle Scholar
• Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients’ quality of life: results of a 2005 National Cutaneous Lymphoma Foundation Survey. Cancer. 2006;107(10):2504–2511. doi:10.1002/cncr.22252.
   PubMed Web of Science ®Google Scholar
• Misery L. Pruritus in cutaneous T-cell lymphomas. In Carstens E, Akiyama T, editors. Itch: mechanisms and treatment. Chapter 8. Boca Raton (FL): CRC Press/Taylor & Francis; 2014. Available from: https://www.ncbi.nlm.nih.gov/books/NBK200941/
   Google Scholar
• Nattkemper LA, Martinez-Escala ME, Gelman AB, et al. Cutaneous T-cell lymphoma and pruritus: the expression of IL-31 and its receptors in the skin. Acta Derm Venereol. 2016;96(7):894–898. doi:10.2340/00015555-2417.
   PubMed Web of Science ®Google Scholar
• Abreu M, Miranda M, Castro M, et al. IL-31 and IL-8 in cutaneous T-cell lymphoma: looking for their role in itch. Adv Hematol. 2021;2021:5582581–5582512. doi:10.1155/2021/5582581.
   PubMedGoogle Scholar
• Ohmatsu H, Sugaya M, Suga H, et al. Serum IL-31 levels are increased in patients with cutaneous T-cell lymphoma. Acta Derm Venereol. 2012;92(3):282–283. doi:10.2340/00015555-1345.
   PubMed Web of Science ®Google Scholar
• van Santen S, Out JJ, Zoutman WH, et al. Serum and cutaneous transcriptional expression levels of IL31 are minimal in cutaneous T cell lymphoma variants. Biochem Biophys Rep. 2021;26:101007. doi:10.1016/j.bbrep.2021.101007.
   PubMedGoogle Scholar
• Cedeno-Laurent F, Singer EM, Wysocka M, et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol. 2015;158(1):1–7. doi:10.1016/j.clim.2015.02.014.
   PubMed Web of Science ®Google Scholar
• Singer EM, Shin DB, Nattkemper LA, et al. IL-31 is produced by the malignant T-cell population in cutaneous T-Cell lymphoma and correlates with CTCL pruritus. J Invest Dermatol. 2013;133(12):2783–2785. doi:10.1038/jid.2013.227.
   PubMed Web of Science ®Google Scholar
• Hu M, Scheffel J, Elieh-Ali-Komi D, et al. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma. Clin Exp Med. 2023;23(8):4177–4197. doi:10.1007/s10238-023-01141-x.
   PubMed Web of Science ®Google Scholar
• Ottevanger R, van Beugen S, Evers AWM, et al. Quality of life in cutaneous T-cell lymphoma patients receiving mogamulizumab: important factors to consider. Cancers (Basel). 2022;15(1):32. doi:10.3390/cancers15010032.
   PubMed Web of Science ®Google Scholar
• Poligone B, Rubio-Gonzalez B, Querfeld C. Relief of intractable pruritus with romidepsin in patients with cutaneous T-cell lymphoma: a series of four cases. Dermatol Ther. 2019;32(2):e12804. doi:10.1111/dth.12804.
   PubMed Web of Science ®Google Scholar
• Field H, Gao L, Motwani P, et al. Pruritus reduction with systemic anti-lymphoma treatments in patients with cutaneous T cell lymphoma: a narrative review. Dermatol Ther (Heidelb). 2016;6(4):579–595. doi:10.1007/s13555-016-0143-4.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Irie H. Interleukin-31 as a clinical target for pruritus treatment. Front Med (Lausanne). 2021;8:638325. doi:10.3389/fmed.2021.638325.
   PubMed Web of Science ®Google Scholar
• Vitale M, Fields-Blache C, Luterman A. Severe itching in the patient with burns. J Burn Care Rehabil. 1991;12(4):330–333.
   PubMedGoogle Scholar
• Nedelec B, LaSalle L. Postburn itch: a review of the literature. Wounds. 2018;30(1):E118–e124.
   PubMed Web of Science ®Google Scholar
• Zachariah JR, Rao AL, Prabha R, et al. Post burn pruritus—a review of current treatment options. Burns. 2012;38(5):621–629. doi:10.1016/j.burns.2011.12.003.
   PubMed Web of Science ®Google Scholar
• Holavanahalli RK, Helm PA, Kowalske KJ. Long-term outcomes in patients surviving large burns: the skin. J Burn Care Res. 2010;31(4):631–639. doi:10.1097/BCR.0b013e3181e4ca62.
   PubMed Web of Science ®Google Scholar
• Santos FX, Arroyo C, García I, et al. Role of mast cells in the pathogenesis of postburn inflammatory response: reactive oxygen species as mast cell stimulators. Burns. 2000;26(2):145–147. doi:10.1016/s0305-4179(99)00021-2.
   PubMed Web of Science ®Google Scholar
• Brooks JP, Malic CC, Judkins KC. Scratching the surface—managing the itch associated with burns: a review of current knowledge. Burns. 2008;34(6):751–760. doi:10.1016/j.burns.2007.11.015.
   PubMed Web of Science ®Google Scholar
• Shimizu S, Tanaka H, Sakaki S, et al. Burn depth affects dermal interstitial fluid pressure, free radical production, and serum histamine levels in rats. J Trauma Acute Care Surg. 2002;52(4):683–687.
   Google Scholar
• Goutos I, Eldardiri M, Khan AA, et al. Comparative evaluation of antipruritic protocols in acute burns. The emerging value of gabapentin in the treatment of burns pruritus. J Burn Care Res. 2010;31(1):57–63. doi:10.1097/BCR.0b013e3181cb8ecf.
   PubMed Web of Science ®Google Scholar
• Kaul I, Amin A, Rosenberg M, et al. Use of gabapentin and pregabalin for pruritus and neuropathic pain associated with major burn injury: A retrospective chart review. Burns. 2018;44(2):414–422. doi:10.1016/j.burns.2017.07.018.
   PubMed Web of Science ®Google Scholar
• Ahuja RB, Gupta R, Gupta G, et al. A comparative analysis of cetirizine, gabapentin and their combination in the relief of post-burn pruritus. Burns. 2011;37(2):203–207. doi:10.1016/j.burns.2010.06.004.
   PubMed Web of Science ®Google Scholar
• Goutos I, Clarke M, Upson C, et al. Review of therapeutic agents for burns pruritus and protocols for management in adult and paediatric patients using the GRADE classification. Indian J Plast Surg. 2010;43(Suppl):S51–S62. doi:10.4103/0970-0358.70721.
   PubMedGoogle Scholar
• Andrade LF, Abdi P, Kooner A, et al. Treatment of post-burn pruritus - a systematic review and meta-analysis. Burns. 2024;50(2):293–301. doi:10.1016/j.burns.2023.09.012.
   PubMed Web of Science ®Google Scholar
• Finnerty CC, Jeschke MG, Branski LK, et al. Hypertrophic scarring: the greatest unmet challenge after burn injury. Lancet. 2016;388(10052):1427–1436. doi:10.1016/S0140-6736(16)31406-4.
   PubMed Web of Science ®Google Scholar
• Hultman CS, Edkins RE, Lee CN, et al. Shine on: review of laser- and light-based therapies for the treatment of burn scars. Dermatol Res Pract. 2012;2012:243651–243659. doi:10.1155/2012/243651.
   PubMedGoogle Scholar
• Hawash AA, Ingrasci G, Nouri K, et al. Pruritus in keloid scars: mechanisms and treatments. Acta Derm Venereol. 2021;101(10):adv00582. doi:10.2340/00015555-3923.
   PubMed Web of Science ®Google Scholar
• Lee SS, Yosipovitch G, Chan YH, et al. Pruritus, pain, and small nerve fiber function in keloids: a controlled study. J Am Acad Dermatol. 2004;51(6):1002–1006. doi:10.1016/j.jaad.2004.07.054.
   PubMed Web of Science ®Google Scholar
• Kouotou EA, Nansseu JR, Omona Guissana E, et al. Epidemiology and clinical features of keloids in Black Africans: a nested case-control study from Yaoundé, Cameroon. Int J Dermatol. 2019;58(10):1135–1140. doi:10.1111/ijd.14610.
   PubMed Web of Science ®Google Scholar
• Kassi K, Kouame K, Kouassi A, et al. Quality of life in black African patients with keloid scars. Dermatol Reports. 2020;12(2):8312. doi:10.4081/dr.2020.8312.
   PubMed Web of Science ®Google Scholar
• Ingrasci G, El-Kashlan N, Alexis A, et al. Chronic itch in African Americans: an unmet need. Arch Dermatol Res. 2022;314(5):405–415. doi:10.1007/s00403-021-02255-6.
   PubMed Web of Science ®Google Scholar
• Biazus Soares G, Mahmoud O, Yosipovitch G. Pruritus in keloid scars: mechanisms and treatments. Ital J Dermatol Venerol. 2023;158(5):401–407. doi:10.23736/S2784-8671.23.07554-0.
   PubMedGoogle Scholar
• Ekstein SF, Wyles SP, Moran SL, et al. Keloids: a review of therapeutic management. Int J Dermatol. 2021;60(6):661–671. doi:10.1111/ijd.15159.
   PubMed Web of Science ®Google Scholar
• Hoang D, Reznik R, Orgel M, et al. Surgical excision and adjuvant brachytherapy vs external beam radiation for the effective treatment of keloids: 10-year institutional retrospective analysis. Aesthet Surg J. 2017;37(2):212–225. doi:10.1093/asj/sjw124.
   PubMed Web of Science ®Google Scholar
• Ma Q-Y, Yang Y-T, Chen Z-A, et al. Laser combined with radiotherapy for keloid treatment: a novel and efficient comprehensive therapy with a lower recurrence rate. Plast Reconstr Surg. 2023;152(6):1022e–1029e. doi:10.1097/PRS.0000000000010376.
   PubMed Web of Science ®Google Scholar
• Hung Y-T, Lin S-M, Tzeng IS, et al. Optimizing surgical outcome of auricular keloid with a novel multimodal approach. Sci Rep. 2022;12(1):3533. doi:10.1038/s41598-022-07255-8.
   PubMed Web of Science ®Google Scholar
• Yosipovitch G, Widijanti Sugeng M, Goon A, et al. A comparison of the combined effect of cryotherapy and corticosteroid injections versus corticosteroids and cryotherapy alone on keloids: a controlled study. J Dermatolog Treat. 2001;12(2):87–90. doi:10.1080/095466301317085363.
   PubMed Web of Science ®Google Scholar
• Kim HS, Hashimoto T, Fischer K, et al. Scabies itch: an update on neuroimmune interactions and novel targets. Acad Dermatol Venereol. 2021;35(9):1765–1776. doi:10.1111/jdv.17334.
   PubMed Web of Science ®Google Scholar
• Jannic A, Bernigaud C, Brenaut E, et al. Scabies itch. Dermatol Clin. 2018;36(3):301–308. doi:10.1016/j.det.2018.02.009.
   PubMed Web of Science ®Google Scholar
• Shin K, Jin H, You HS, et al. Clinical characteristics of pruritus in scabies. Indian J Dermatol Venereol Leprol. 2017;83(4):492–493. doi:10.4103/ijdvl.IJDVL_1136_16.
   PubMed Web of Science ®Google Scholar
• Lavery MJ, Stull C, Kinney MO, et al. Nocturnal pruritus: the battle for a peaceful night’s sleep. Int J Mol Sci. 2016;17(3):425. doi:10.3390/ijms17030425.
   PubMed Web of Science ®Google Scholar
• Rosumeck S, Nast A, Dressler C. Ivermectin and permethrin for treating scabies. Cochrane Database Syst Rev. 2018;4(4):Cd012994. doi:10.1002/14651858.CD012994.
   PubMedGoogle Scholar
• Sanders KM, Nattkemper LA, Rosen JD, et al. Non-histaminergic itch mediators elevated in the skin of a porcine model of scabies and of human scabies patients. J Invest Dermatol. 2019;139(4):971–973. doi:10.1016/j.jid.2018.09.032.
   PubMed Web of Science ®Google Scholar
• Zagoras T, Inci R, Kantere D, et al. Incidence and prevalence of 73 different genodermatoses: a nationwide study in Sweden. Acta Derm Venereol. 2023;103:adv12404. doi:10.2340/actadv.v103.12404.
   PubMed Web of Science ®Google Scholar
• Kridin K, Kneiber D, Kowalski EH, et al. Epidermolysis bullosa acquisita: a comprehensive review. Autoimmun Rev. 2019;18(8):786–795. doi:10.1016/j.autrev.2019.06.007.
   PubMed Web of Science ®Google Scholar
• Wally V, Reisenberger M, Kitzmüller S, et al. Small molecule drug development for rare genodermatoses – evaluation of the current status in epidermolysis bullosa. Orphanet J Rare Dis. 2020;15(1):292. doi:10.1186/s13023-020-01467-9.
   PubMed Web of Science ®Google Scholar
• Pabón-Carrasco M, Caceres-Matos R, Roche-Campos M, et al. Management of skin lesions in patients with epidermolysis bullosa by topical treatment: systematic review and meta-analysis. Healthcare (Basel). 2024;12(2):261. doi:10.3390/healthcare12020261.
   Google Scholar
• Danial C, Adeduntan R, Gorell ES, et al. Prevalence and characterization of pruritus in epidermolysis bullosa. Pediatr Dermatol. 2015;32(1):53–59. doi:10.1111/pde.12391.
   PubMed Web of Science ®Google Scholar
• Mellerio JE, Pillay EI, Ledwaba-Chapman L, et al. Itch in recessive dystrophic epidermolysis bullosa: findings of PEBLES, a prospective register study. Orphanet J Rare Dis. 2023;18(1):235. doi:10.1186/s13023-023-02817-z.
   PubMed Web of Science ®Google Scholar
• Understanding itch in epidermolysis bullosa (EB). Br J Dermatol. 2021;184(5):e177–e177.
   Web of Science ®Google Scholar
• Jeon IK, On HR, Kim SC. Quality of life and economic burden in recessive dystrophic epidermolysis bullosa. Ann Dermatol. 2016;28(1):6–14. doi:10.5021/ad.2016.28.1.6.
   PubMed Web of Science ®Google Scholar
• Kern JS, Sprecher E, Fernandez MF, et al. Efficacy and safety of Oleogel-S10 (birch triterpenes) for epidermolysis bullosa: results from the phase III randomized double-blind phase of the EASE study. Br J Dermatol. 2023;188(1):12–21. doi:10.1093/bjd/ljac001.
   PubMed Web of Science ®Google Scholar
• Dhillon S. Beremagene geperpavec: first approval. Drugs. 2023;83(12):1131–1135. doi:10.1007/s40265-023-01921-5.
   PubMed Web of Science ®Google Scholar
• Guide SV, Gonzalez ME, Bağcı IS, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211–2219. doi:10.1056/NEJMoa2206663.
   PubMed Web of Science ®Google Scholar
• Niazi M, Parvizi MM, Saki N, et al. Efficacy of a topical formulation of henna (Lawsonia inermis Linnaeus) on the itch and wound healing in patients with epidermolysis bullosa: a pilot single-arm clinical trial. Dermatol Pract Concept. 2022;12(3):e2022115. doi:10.5826/dpc.1203a115.
   PubMedGoogle Scholar
• Paller AS, Browning J, Nikolic M, et al. Efficacy and tolerability of the investigational topical cream SD-101 (6% allantoin) in patients with epidermolysis bullosa: a phase 3, randomized, double-blind, vehicle-controlled trial (ESSENCE study). Orphanet J Rare Dis. 2020;15(1):158. doi:10.1186/s13023-020-01419-3.
   PubMed Web of Science ®Google Scholar
• Prodinger C, Reichelt J, Bauer JW, et al. Epidermolysis bullosa: advances in research and treatment. Exp Dermatol. 2019;28(10):1176–1189. doi:10.1111/exd.13979.
   PubMed Web of Science ®Google Scholar
• Papanikolaou M, Nattkemper L, Benzian-Olsson N, et al. Th2 response drives itch in dystrophic epidermolysis bullosa pruriginosa: a case-control study. J Am Acad Dermatol. 2024. doi:10.1016/j.jaad.2024.01.088.
   PubMedGoogle Scholar
• Shehadeh W, Sarig O, Bar J, et al. Treatment of epidermolysis bullosa pruriginosa-associated pruritus with dupilumab. Br J Dermatol. 2020;182(6):1495–1497. doi:10.1111/bjd.18855.
   PubMed Web of Science ®Google Scholar
• Mazereeuw-Hautier J, Vahlquist A, Traupe H, et al. Management of congenital ichthyoses: european guidelines of care, part one. Br J Dermatol. 2019;180(2):272–281. doi:10.1111/bjd.17203.
   PubMed Web of Science ®Google Scholar
• Butala S, Mazereeuw-Hautier J, Paller AS. Ichthyosis: presentation and management. Curr Opin Pediatr. 2023;35(4):467–474. doi:10.1097/MOP.0000000000001264.
   PubMed Web of Science ®Google Scholar
• De Palma AM, Mazereeuw-Hautier J, Giehl K, et al. Burden of itch in ichthyosis: a multicentre study in 94 patients. J Eur Acad Dermatol Venereol. 2019;33(11):2095–2100. doi:10.1111/jdv.15613.
   PubMed Web of Science ®Google Scholar
• Rabinowitz LG, Esterly NB. Atopic dermititis and ichthyosis vulgaris. Pediatr Rev. 1994;15(6):220–226; quiz 226. doi:10.1542/pir.15-6-220.
   PubMedGoogle Scholar
• Benintende C, Boscaglia S, Dinotta F, et al. Treatment of ichthyosis vulgaris with a urea-based emulsion: videodermatoscopy and confocal microscopy evaluation. G Ital Dermatol Venereol. 2017;152(6):555–559. doi:10.23736/S0392-0488.17.05743-1.
   PubMed Web of Science ®Google Scholar
• Dorf ILH, Lunen MS, Koppelhus U. Effect of topical treatment with 7.5% urea in Ichthyosis Vulgaris: A randomized, controlled, double blinded, split body study evaluating the effect of urea cream compared to the vehicle (moisturizing) cream. Skin Health Dis. 2021;1(4):e65.
   PubMedGoogle Scholar
• Vahlquist A, Gånemo A, Virtanen M. Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol. 2008;88(1):4–14. doi:10.2340/00015555-0415.
   PubMed Web of Science ®Google Scholar
• Barbati F, Giovannini M, Oranges T, et al. Netherton syndrome in children: management and future perspectives. Front Pediatr. 2021;9:645259. doi:10.3389/fped.2021.645259.
   PubMed Web of Science ®Google Scholar
• Cortés H, Del Prado-Audelo ML, Urbán-Morlán Z, et al. Pharmacological treatments for cutaneous manifestations of inherited ichthyoses. Arch Dermatol Res. 2020;312(4):237–248. doi:10.1007/s00403-019-01994-x.
   PubMed Web of Science ®Google Scholar
• Peña-Corona SI, Gutiérrez-Ruiz SC, Echeverria M, et al. Advances in the treatment of autosomal recessive congenital ichthyosis, a look towards the repositioning of drugs. Front Pharmacol. 2023;14:1274248. doi:10.3389/fphar.2023.1274248.
   PubMed Web of Science ®Google Scholar
• Joosten MDW, Clabbers JMK, Jonca N, et al. New developments in the molecular treatment of ichthyosis: review of the literature. Orphanet J Rare Dis. 2022;17(1):269. doi:10.1186/s13023-022-02430-6.
   PubMed Web of Science ®Google Scholar
• Dev T, Mahajan VK, Sethuraman G. Hereditary palmoplantar keratoderma: a practical approach to the diagnosis. Indian Dermatol Online J. 2019;10(4):365–379. doi:10.4103/idoj.IDOJ_367_18.
   PubMedGoogle Scholar
• Bodemer C, Steijlen P, Mazereeuw-Hautier J, et al. Treatment of hereditary palmoplantar keratoderma: a review by analysis of the literature*. Br J Dermatol. 2021;184(3):393–400. doi:10.1111/bjd.19144.
   PubMed Web of Science ®Google Scholar
• Huang Y-Y, Li J-H. Olmsted syndrome. JAMA Dermatol. 2024;160(2):218–219. doi:10.1001/jamadermatol.2023.4152.
   PubMed Web of Science ®Google Scholar
• Kataria V, Grover C, Pandhi D. Palmo-plantar keratoderma with debilitating pruritus. Indian J Paediatr Dermatol. 2020;21(3):187–190. doi:10.4103/ijpd.IJPD_4_20.
   Google Scholar
• Duchatelet S, Hovnanian A. Olmsted syndrome: clinical, molecular and therapeutic aspects. Orphanet J Rare Dis. 2015;10(1):33. doi:10.1186/s13023-015-0246-5.
   PubMedGoogle Scholar
• Greco C, Leclerc-Mercier S, Chaumon S, et al. Use of epidermal growth factor receptor inhibitor erlotinib to treat palmoplantar keratoderma in patients with olmsted syndrome caused by TRPV3 mutations. JAMA Dermatol. 2020;156(2):191–195. doi:10.1001/jamadermatol.2019.4126.
   PubMed Web of Science ®Google Scholar